Terns Pharmaceuticals is planning to stop investing in metabolic disease clinical development by year-end, starting a countdown to potential deals for assets including a midphase oral obesity prospect ...
Terns Pharmaceuticals is a clinical-stage biotech focused on oncology and obesity, with its key TERN-601 obesity program seeking a partner. TERN-601 faces tough competition in the oral GLP-1 obesity ...
Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results